Placebo matching to spesolimab

DRUG3 trials

Sponsors

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A., LEO Pharma

Conditions

Hidradenitis Suppurativa (HS)Pyoderma GangrenosumPyoderma gangrenosum

Phase 2

Lunsayil LTE: An extension trial assessing long-term spesolimab treatment in patients with Hidradenitis Suppurativa (HS)

CompletedCTIS2023-508377-82-00

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.Hidradenitis Suppurativa (HS)

Start: 2024-06-27End: 2025-03-31Target: 99Updated: 2025-02-11

Phase 3

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

RecruitingNCT06624670

LEO PharmaPyoderma Gangrenosum

Start: 2025-02-05End: 2028-08-19Target: 90Updated: 2026-09-02

A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy

RecruitingCTIS2024-514306-31-00

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.Pyoderma gangrenosum

Start: 2025-02-13Target: 34Updated: 2025-12-15

Related Papers

Aseptic meningitis due to intravenous immunoglobulin therapy (IVIG) in therapy‐refractory pyoderma gangraenosum

JDDG Journal der Deutschen Dermatologischen Gesellschaft2026-03-25